pharma · Symptomatic hypertrophic cardiomyopathy (HCM) · SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Cytokinetics
Cytokinetics (Ireland) Limited
Cytokinetics (Ireland) is a pharma organization headquartered in GB. Primary therapeutic focus areas include Symptomatic hypertrophic cardiomyopathy (HCM), SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY, Heart Failu
South San Francisco, USA HQ
1998 Founded
759 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 1998
- Employees
- 759
- Programs
- 5
- Drugs
- 7
- Patents
- 0
CY 1033
Phase 3 · small molecule · Heart Failure With Reduced Ejection Fraction
CY 1033 for Heart Failure With Reduced Ejection Fraction is a Phase 3 program (small_molecule) at Cytokinetics (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Internal code CY 1033
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Cytokinetics (Ireland) Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Heart Failure With Reduced Ejection Fraction
- Status
- active
- Trials
- 1